Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20050232972 A1
Publication typeApplication
Application numberUS 10/825,047
Publication dateOct 20, 2005
Filing dateApr 15, 2004
Priority dateApr 15, 2004
Also published asUS20100040670, US20120277694, US20150132358
Publication number10825047, 825047, US 2005/0232972 A1, US 2005/232972 A1, US 20050232972 A1, US 20050232972A1, US 2005232972 A1, US 2005232972A1, US-A1-20050232972, US-A1-2005232972, US2005/0232972A1, US2005/232972A1, US20050232972 A1, US20050232972A1, US2005232972 A1, US2005232972A1
InventorsSteven Odrich
Original AssigneeSteven Odrich
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Drug delivery via punctal plug
US 20050232972 A1
Abstract
A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.
Images(2)
Previous page
Next page
Claims(19)
1. A method for administering an active agent to a subject, the active agent having been applied to at least one surface of an ocular implant, the method comprising installing the implant at the eye of the subject for administering the active agent through tissues of the eye.
2. A method according to claim 1, including the step of applying the active agent to at least one surface of the ocular implant.
3. A method according to claim 1, wherein the ocular implant is a punctal plug, the method including inserting the plug into a punctal aperture of the subject.
4. A method according to claim 1, wherein the ocular implant is a punctal plug, the method including applying the active agent to a stem of the plug and inserting the stem into a canaliculus of the subject.
5. A method according to claim 1, wherein the ocular implant is a punctal plug, the method including applying the active agent to a stopper of the plug, the plug having a stem for inserting into a punctal aperture of the subject.
6. A method according to claim 1, wherein the active agent is a medicine.
7. A method according to claim 1, wherein the active agent is selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimataprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a mediation for treating hypertension; atenolol; nifedipine; and hydrochlorothiazide.
8. A method according to claim 1, wherein the active agent is a medication for the topical treatment of glaucoma or corneal infection.
9. A method according to claim 1, wherein the implant is hollow for passing tears.
10. A method according to claim 1, wherein the implant is hollow for passing tears and the active agent is made available at an interior of the hollow implant for being carried by the passage of tears.
11. An apparatus for administering an active agent to a subject, comprising an active agent applied to at least one surface of an ocular implant for installation at the eye of the subject.
12. An apparatus according to claim 11, wherein the ocular implant is a punctal plug.
13. An apparatus according to claim 11, wherein the ocular implant is a punctal plug, the active agent being on a stem of the plug for insertion into a canaliculus of the subject.
14. An apparatus according to claim 11, wherein the ocular implant is a punctal plug, the active agent being on a stopper of the plug, the plug having a stem for insertion into a punctal aperture of the subject.
15. An apparatus according to claim 11, wherein the active agent is a medicine.
16. An apparatus according to claim 11, wherein the active agent is selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimataprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a mediation for treating hypertension; atenolol; nifedipine; and hydrochlorothiazide.
17. An apparatus according to claim 11, wherein the active agent is a medication for the topical treatment of glaucoma or corneal infection.
18. An apparatus according to claim 11, wherein the implant is hollow for passing tears.
19. An apparatus according to claim 11, wherein the implant is hollow for passing tears and the active agent is made available at an interior of the hollow implant.
Description
    FIELD AND BACKGROUND OF THE INVENTION
  • [0001]
    The present invention relates generally to the field of medicine, and in particular to a new and useful method and apparatus for administering an active agent, i.e. a medicine or medication, to a subject by transdermal or other surface absorption of the agent into the tissues in and around one or both eyes of the subject.
  • [0002]
    Punctal plugs are known which are made in suitable dimensions and of suitable materials to be removably inserted into the upper and/or lower punctal apertures or punctum of the eye, to block the opening and the canaliculus communicating therewith, to prevent drainage of lacrimal fluid (tears). Such plugs are known to be made of suitable materials, such as polymers, for example polytetrafluorethylene (known by the trademark TEFLON), or hydroxyethylmethacrylate (HEMA), hydrophilic polymer, methyl methacrylate, or silicon, or even of stainless steel or other inert metal material.
  • [0003]
    It is also known to apply an active agent such as nicotine or a birth control drug, to the inner surface of a patch which can be worn against the skin of a subject for transdermally administering the active agent to the subject.
  • SUMMARY OF THE INVENTION
  • [0004]
    It is an object of the present invention to provide a method and an apparatus for administering an active agent to a subject by applying the active agent to at least one surface of an ocular implant such as a punctal plug, and installing the implant, e.g. inserting the punctal plug into a punctal aperture of the subject.
  • [0005]
    If the active agent or drug is meant for treating the tissues at the walls of the canaliculus, for example, the drug is applied only to inner surfaces of the plug that are adapted to be in contact with or near the tissues of the canaliculus. The presence of tears is highly advantageous as a natural vehicle or carrier for the agent.
  • [0006]
    If the active agent or drug is meant for treating the eye itself, the drug is applied only to outer surfaces of the implant or plug that are adapted to be outside the canaliculus. Here the presence of previously secreted tears or a tear pool is again advantageous as a natural vehicle or carrier for the agent.
  • [0007]
    Any or all surfaces of the implant may carry the active agent there the desire is simply to have the agent enter the subjects blood stream via the tissues in and around the eye.
  • [0008]
    The various features of novelty which characterize the invention are pointed out with particularity in the claims annexed to and forming a part of this disclosure. For a better understanding of the invention, its operating advantages and specific objects attained by its uses, reference is made to the accompanying drawings and descriptive matter in which preferred embodiments of the invention are illustrated.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0009]
    In the drawings:
  • [0010]
    FIG. 1 is a schematic perspective view of an ocular implant in the form of a punctal plug according to the present invention; and
  • [0011]
    FIG. 2 is a perspective view of the area around the eye with other embodiments of the invention.
  • DESCRIPTION OF THE PREFERRED EMBODIMENT
  • [0012]
    Referring now to the drawing, FIG. 1 shows a punctal plug generally designated 10, having a stem 12 for insertion into the punctal aperture 20 of an eye 24, and along the canaliculus 22 communicating with the aperture.
  • [0013]
    Plug 10 has a large stopper structure 14 connected to the outer end of stem 12 for seating against the aperture 20 and sealing the canaliculus 22 against the flow of tears onto the surface of the eye or eyeball 24.
  • [0014]
    FIG. 2, where the same of similar numerals are used to designate functionally similar parts, illustrates an eye 24 communicating with upper and lower canaliculi 22 a and 22 b, each with their our implant 10 a and 10 b. Implant 10 a is a substantially cylindrical and solid collagen plug that has been inserted into the upper punctum or tear duct 20 a, to block the flow of tears while lower implant 10 b is hollow like a straw for the passage of tears. Implant 10 b includes a tapered shaft or stem 12 a with a flared open end 12 b immobilized at the lower punctum 20 b. A mushroom shaped inner stopper 14 a is formed at the opposite end of shaft 12 a for further setting the location of the implant in the tear duct.
  • [0015]
    One of the embodiments illustrated in FIG. 2, e.g. the upper implant, may include a hollow core of the plug and another, e.g. the lower one, may include a hollow core filled with medication.
  • [0016]
    The active agent, e.g. a medicine or medication is applied, e.g. in one or more bands of polymer material 16 at the inner end of the stem, or at 18 on the outer end of the stopper 14 in the embodiment of FIG. 1, or over some or all of the surfaces of the implants of FIG. 2, or otherwise. Polymer that is absorbent to the agent is preferable so that sufficient agent is present and available for discharge into the surrounding tissues. A porous or absorbent material can alternatively be used to make up the entire plug or implant which can be saturated with the active agent.
  • [0017]
    The hollow implant 10 b of FIG. 2 is also particularly useful in that the active agent can be applied to, or is otherwise available at the inner surface or interior of the implant, and is uniquely structured to pass tears and thus administer the active agent to the tear stream in a fashion that is controlled by the flow of tears which thus act as the carrier for the agent. Unlike the usual tear stopping punctal plug, the hollow implant of the present invention provides a very different drug administering method, scheme and structure.
  • [0018]
    Non-limiting examples of the active agents or medications which are appropriate for use with the invention include, for example only: topical prostaglandin derivatives such as latanoprost, travaprost and bimataprost used for the topical treatment of glaucoma. Also a treatment for corneal infections is appropriate using ciprofloxacin, moxifloxacin or gatifloxacin. Systemic medications useful for this invention are those used for hypertension such as atenolol, nifedipine or hydrochlorothiazide. Any other chronic disease requiring chronic medication could be used.
  • [0019]
    The treatment of allergic conjunctivitis and rhinitis are also good applications for the invention, e.g. using antihistamine and anti-allergy medication such as olopatadine and cromalyn sodium in or on the implant.
  • [0020]
    The advantage is that there would be no need for chronic pill-taking or drop taking. A once-per 3-6 month visit to the eye doctor would be all that is needed. Also the issue of non-compliance, a major impediment to successful treatment, would by avoided by the invention.
  • [0021]
    This list of active agents is not comprehensive in that many other agents can be used with the present invention. For example, a treatment for dry eye bytopical cyclosporin is particularly interesting for administration by the present invention, but many other active agents can also be administered using the method and apparatus of the invention.
  • [0022]
    The invention is meant to embody all implants or devices which are implanted into the eye-lid canalicular puncta of the naso-lacrimal system with the goal of delivering drug to the eye or to the body.
  • [0023]
    The implant is inserted into either the inferior (lower) or superior (upper) punctum or possibly both. The apparatus is constructed so as to have a drug attached to one or both sides of the implant and an occlusive plug of some inert biocompatible material.
  • [0024]
    Depending on the desired therapy, the implant could be oriented in the punctal canal to deliver the drug either to the tear lake and thus the eye, or to the nasolacrimal system and thus the body's systemic circulation. The drawings illustrate only three embodiments of the punctal plug or implant delivery system of the invention.
  • [0025]
    While a specific embodiment of the invention has been shown and described in detail to illustrate the application of the principles of the invention, it will be understood that the invention may be embodied otherwise without departing from such principles.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US577319 *Sep 4, 1895Feb 16, 1897 pfeiffer
US3828777 *Nov 8, 1971Aug 13, 1974Alza CorpMicroporous ocular device
US3865108 *Jul 9, 1973Feb 11, 1975Ortho Pharma CorpExpandable drug delivery device
US3949750 *Oct 7, 1974Apr 13, 1976Freeman Jerre MPunctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same
US4014335 *Mar 25, 1976Mar 29, 1977Alza CorporationOcular drug delivery device
US4281654 *Apr 7, 1980Aug 4, 1981Alza CorporationDrug delivery system for controlled ocular therapy
US4660546 *Nov 7, 1984Apr 28, 1987Robert S. HerrickMethod for treating for deficiency of tears
US4915684 *Jun 21, 1988Apr 10, 1990Mackeen Donald LMethod and apparatus for modulating the flow of lacrimal fluid through a punctum and associated canaliculus
US4959048 *Jan 17, 1989Sep 25, 1990Helix Medical, Inc.Lacrimal duct occluder
US5041081 *May 18, 1990Aug 20, 1991Odrich Ronald BOcular implant for controlling glaucoma
US5049142 *Aug 2, 1988Sep 17, 1991Herrick Robert SIntracanalicular implant for horizontal canalicular blockade treatment of the eye
US5053030 *Nov 13, 1986Oct 1, 1991Herrick Robert SIntracanalicular implant for horizontal canalicular blockade treatment of the eye
US5098443 *Feb 6, 1991Mar 24, 1992University Of MiamiMethod of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5116371 *Jul 6, 1990May 26, 1992Christensen James MProsthesis with improved biocompatibility
US5128058 *May 30, 1990Jul 7, 1992Hoya CorporationContact lens cleaner containing a microcapsular polishing agent
US5133159 *Dec 18, 1990Jul 28, 1992Nestle S.A.Method for polishing silicone products
US5283063 *Jan 31, 1992Feb 1, 1994Eagle VisionPunctum plug method and apparatus
US5318513 *Sep 24, 1992Jun 7, 1994Leib Martin LCanalicular balloon fixation stent
US5334137 *Feb 21, 1992Aug 2, 1994Eagle Vision, Inc.Lacrimal fluid control device
US5395618 *May 17, 1994Mar 7, 1995Escalon Ophthalmics, Inc.Ocular insert with anchoring protrusions
US5417651 *Jul 1, 1993May 23, 1995Guena; NicolasPunctum plug and monocanalicular probe for lacrimal pathology
US5423777 *Oct 27, 1993Jun 13, 1995Tajiri; AkiraPunctum plug
US5556633 *Apr 28, 1993Sep 17, 1996Haddad; Heskel M.Drug delivery ophthalmic insert and method for preparing same
US5707643 *Jun 7, 1996Jan 13, 1998Santen Pharmaceutical Co., Ltd.Biodegradable scleral plug
US5723005 *Jun 7, 1995Mar 3, 1998Herrick Family Limited PartnershipPunctum plug having a collapsible flared section and method
US5741292 *Apr 28, 1997Apr 21, 1998Eagle VisionPunctum dilating and plug inserting instrument with push-button plug release
US5766243 *Jul 31, 1996Jun 16, 1998Oasis Medical, Inc.Abrasive polished canalicular implant
US5770589 *Jul 27, 1994Jun 23, 1998The University Of SydneyTreatment of macular degeneration
US5824073 *Sep 20, 1996Oct 20, 1998Peyman; Gholam A.Macular indentor for use in the treatment of subretinal neovascular membranes
US5826584 *Oct 4, 1995Oct 27, 1998Schmitt; Edward E.Devices for occluding channels in living mammals
US5961370 *May 8, 1997Oct 5, 1999Chiron Vision CorporationIntraocular lens tumbling process using coated beads
US5962383 *Sep 3, 1998Oct 5, 1999Kyzen CorporationCleaning compositions and methods for cleaning resin and polymeric materials used in manufacture
US6010391 *Oct 31, 1997Jan 4, 2000Alcon Laboratories, Inc.Cryogenic polishing method for soft acrylic articles
US6016806 *Mar 27, 1997Jan 25, 2000Eaglevision, IncPunctum plug
US6027470 *Jun 10, 1998Feb 22, 2000Eagle Vision, Inc.Punctum plug and method for inserting the same into the punctual opening
US6041785 *Nov 6, 1998Mar 28, 2000Eaglevision, Inc.Punctum plug
US6082362 *May 5, 1999Jul 4, 2000Eagle Vision, Inc.Punctum plug
US6095901 *Dec 9, 1998Aug 1, 2000Alcon Laboratories, Inc.Polishing method for soft acrylic articles
US6196993 *Apr 19, 1999Mar 6, 2001Eyelab Group, LlcOphthalmic insert and method for sustained release of medication to the eye
US6234175 *Jul 27, 1999May 22, 2001Medennium, Inc.Smart ocular plug design and method of insertion for punctal and intracanalicular implants
US6238363 *Feb 24, 1999May 29, 2001Mlc Limited CompanyApparatus for intubation of lacrimal drainage pathway
US6254562 *Feb 4, 1997Jul 3, 2001Alain FouereMeatus plug for lachrymal canal capable of being screwed
US6264971 *Nov 4, 1999Jul 24, 2001Btg International LimitedOcular insert
US6290684 *Mar 2, 1998Sep 18, 2001Herrick Family Limited PartnershipPunctum plug having a collapsible expanded section and distal tip extending substantially perpendicular thereto and method of inserting same
US6306114 *Jun 16, 1998Oct 23, 2001Eagle Vision, Inc.Valved canalicular plug for lacrimal duct occlusion
US6371122 *Jun 20, 2000Apr 16, 2002Robert M. MandelkornGauge/dilator apparatus
US6375972 *Apr 26, 2000Apr 23, 2002Control Delivery Systems, Inc.Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6383192 *Apr 21, 2000May 7, 2002Mlc Limited CompanyApparatus for intubation of lacrimal duct
US6428502 *May 8, 2000Aug 6, 2002Alcon Manufacturing, Ltd.Punctal cannula
US6455062 *Aug 21, 2001Sep 24, 2002Allergan, Inc.Implant device with a retinoid for improved biocompatibility
US6605108 *Apr 13, 2001Aug 12, 2003Eagle Vision, Inc.Monocanalicular stent
US6706275 *Sep 8, 2000Mar 16, 2004Matthew W. CampScleral plug system
US6729939 *Dec 17, 2001May 4, 2004Bausch & Lomb IncorporatedPolishing method for intraocular lens
US6756049 *Dec 17, 2001Jun 29, 2004Bausch & Lomb IncorporatedSustained release drug delivery devices
US6780164 *Mar 21, 2003Aug 24, 2004Glaukos CorporationL-shaped implant with bi-directional flow
US6840931 *Oct 25, 2002Jan 11, 2005Alza CorporationOsmotic delivery system flow modulator apparatus and method
US6846318 *May 20, 2003Jan 25, 2005Matthew W. CampScleral plug system
US6866563 *Jun 27, 2002Mar 15, 2005Bausch & Lomb IncorporatedApparatus and method for target polishing intraocular lenses
US6982090 *May 10, 2001Jan 3, 2006Gillespie Donald EMore easily visualized punctum plug configurations
US6991808 *Jan 23, 2002Jan 31, 2006Bausch & Lomb Inc.Process for the production of sustained release drug delivery devices
US6994684 *Jun 16, 2003Feb 7, 2006Alphamed Inc.Punctum plugs having fluid collecting recesses and methods of punctal occlusion
US7017580 *May 22, 2003Mar 28, 2006Clarity CorporationPunctum plug system including a punctum plug and passive insertion tool therefor
US7204253 *Oct 14, 2004Apr 17, 2007Clarity CorporationPunctum plug
US7204995 *Jan 31, 2003Apr 17, 2007El-Sherif Dalia MTreatment and control of dry eye by use of biodegradable polymer capsules
US20020032400 *May 22, 2001Mar 14, 2002Moazed Kambiz ThomasTransnasal lacrimal insert
US20020055701 *Jan 31, 2001May 9, 2002Fischell Robert E.Surgically implanted devices having reduced scar tissue formation
US20020151960 *Apr 13, 2001Oct 17, 2002Mendius Richard W.Monocanalicular stent
US20030130612 *Feb 25, 2003Jul 10, 2003Moazed Kambiz ThomasTransnasal lacrimal insert
US20040102729 *Aug 5, 2003May 27, 2004David HaffnerDevices and methods for glaucoma treatment
US20040121014 *Nov 14, 2003Jun 24, 2004Control Delivery Systems, Inc.Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040127843 *Nov 12, 2003Jul 1, 2004Hosheng TuGlaucoma implant with therapeutic agents
US20040137068 *Dec 22, 2003Jul 15, 2004Rajiv BhushanOphthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye
US20040141151 *Jan 9, 2004Jul 22, 2004Gillespie Donald E.More easily visualized punctum plug configurations
US20040147870 *Oct 28, 2003Jul 29, 2004Burns Thomas W.Glaucoma treatment kit
US20040170685 *Feb 26, 2004Sep 2, 2004Medivas, LlcBioactive stents and methods for use thereof
US20040175410 *Jan 22, 2004Sep 9, 2004Control Delivery Systems, Inc.Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US20050048121 *Jun 4, 2004Mar 3, 2005Polymerix CorporationHigh molecular wegiht polymers, devices and method for making and using same
US20050095269 *Nov 4, 2003May 5, 2005Ainpour Parviz R.Gel plug for blockage of the canaliculus
US20050129731 *Nov 3, 2004Jun 16, 2005Roland HorresBiocompatible, biostable coating of medical surfaces
US20050197614 *Mar 4, 2005Sep 8, 2005Wilson PritchardOcclusive biomedical devices, punctum plugs, and methods of use thereof
US20060013835 *Sep 12, 2005Jan 19, 2006Anderson Aron BControlled release bioactive agent delivery device
US20060020248 *Jul 26, 2004Jan 26, 2006Prescott Anthony DLacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
US20060020253 *Jul 26, 2004Jan 26, 2006Prescott Anthony DImplantable device having reservoir with controlled release of medication and method of manufacturing the same
US20060074370 *Sep 24, 2004Apr 6, 2006Medennium, Inc.Ocular occluder and method of insertion
US20060100700 *Jul 1, 2003May 11, 2006Pascal BernardMeatal occluder for closing a lachrymal meatus
US20060106352 *May 26, 2004May 18, 2006Katsuaki KurihashiLacrimal punctum plug
US20060122553 *Sep 5, 2003Jun 8, 2006Khalil HannaClosure cap for lachrymal canaliculus
US20070083146 *Oct 7, 2005Apr 12, 2007Murray George WPunctum plugs having insertion guides and strengthening beams
US20070132125 *Nov 13, 2006Jun 14, 2007Bausch & Lomb IncorporatedUse of a super-cooled fluid in lens processing
US20070135914 *Nov 30, 2006Jun 14, 2007Herrick Robert S IiImplant capable of forming a differential image in an eye and methods of inserting and locating same
US20070197614 *Feb 20, 2007Aug 23, 2007Sanofi-Aventis Deutschland GmbhMethod for the production of diarylcycloalkyl derivatives
US20080038317 *Sep 7, 2005Feb 14, 2008Chin-Ming ChangTherapeutic Lacrimal Canalicular Inserts And Related Methods
US20080045878 *Aug 20, 2007Feb 21, 2008Glaukos CorporationTherapeutic shunt device and method for treating glaucoma
US20080045911 *Jun 7, 2007Feb 21, 2008Borgia Maureen JPunctal plugs for the delivery of active agents
US20090092654 *Dec 10, 2008Apr 9, 2009Qlt Plug Delivery, Inc.Drug Delivery Methods, Structures, and Compositions for Nasolacrimal System
US20090104243 *Sep 5, 2008Apr 23, 2009Qlt Plug Delivery, Inc. - QpdiDrug cores for sustained release of therapeutic agents
US20090104248 *Sep 8, 2008Apr 23, 2009Qlt Plug Delivery, Inc. -QpdiLacrimal implants and related methods
US20090105749 *Sep 5, 2008Apr 23, 2009Qlt Plug Delivery, Inc. - QpdiInsertion and extraction tools for lacrimal implants
US20090118702 *Jul 1, 2005May 7, 2009Forsight Labs, LlcTreatment Medium Delivery Device and Methods for Delivery of Such Treatment Mediums to the Eye Using such a Delivery Device
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7815592Apr 22, 2008Oct 19, 2010Transcend Medical, Inc.Ocular pressure regulation
US7850638Dec 14, 2010Transcend Medical, Inc.Ocular pressure regulation
US7922702Jul 1, 2005Apr 12, 2011Qlt Inc.Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US7998497Aug 16, 2011Qlt Inc.Nasolacrimal drainage system implants for drug therapy
US8167939May 1, 2012Transcend Medical, Inc.Ocular implant with stiffness qualities, methods of implantation and system
US8172899May 8, 2012Transcend Medical, Inc.Ocular implant with stiffness qualities, methods of implantation and system
US8262726Oct 5, 2010Sep 11, 2012Transcend Medical, Inc.Ocular implant with stiffness qualities, methods of implantation and system
US8333726Sep 8, 2008Dec 18, 2012Qlt Inc.Lacrimal implants and related methods
US8377122Jan 27, 2010Feb 19, 2013Transcend Medical, Inc.Ocular implant with stiffness qualities, methods of implantation and system
US8409606Feb 12, 2010Apr 2, 2013Incept, LlcDrug delivery through hydrogel plugs
US8444588May 21, 2013Transcend Medical, Inc.Internal shunt and method for treating glaucoma
US8486000Nov 12, 2004Jul 16, 2013Transcend Medical, Inc.Ocular pressure regulation
US8529492Dec 20, 2010Sep 10, 2013Trascend Medical, Inc.Drug delivery devices and methods
US8563027Feb 26, 2013Oct 22, 2013Incept, LlcDrug delivery through hydrogel plugs
US8574294Dec 16, 2010Nov 5, 2013Transcend Medical, Inc.Ocular implant with stiffness qualities, methods of implantation and system
US8617139Jun 25, 2009Dec 31, 2013Transcend Medical, Inc.Ocular implant with shape change capabilities
US8628792Feb 7, 2012Jan 14, 2014Mati Therapeutics, Inc.Drug cores for sustained release of therapeutic agents
US8672870Jul 17, 2008Mar 18, 2014Transcend Medical, Inc.Ocular implant with hydrogel expansion capabilities
US8691265 *Oct 4, 2012Apr 8, 2014Mati Therapeutics, Inc.Drug delivery methods, structures, and compositions for nasolacrimal system
US8702643Aug 29, 2012Apr 22, 2014Mati Therapeutics, Inc.Lacrimal implants and related methods
US8721656Dec 22, 2006May 13, 2014Transcend Medical, Inc.Glaucoma treatment device
US8728021Dec 17, 2010May 20, 2014Transcend Medical, Inc.Ocular pressure regulation
US8734378Sep 17, 2009May 27, 2014Transcend Medical, Inc.Glaucoma treatment device
US8747884Jul 18, 2011Jun 10, 2014Mati Therapeutics Inc.Nasolacrimal drainage system implants for drug therapy
US8753666Jan 30, 2008Jun 17, 2014Alcon Research, Ltd.Punctal plugs and methods of delivering therapeutic agents
US8758289Dec 17, 2010Jun 24, 2014Transcend Medical, Inc.Ocular pressure regulation
US8765166Jul 22, 2013Jul 1, 2014Novaer Holdings, Inc.Drug delivery devices for delivery of ocular therapeutic agents
US8771218Dec 17, 2010Jul 8, 2014Transcend Medical, Inc.Ocular pressure regulation
US8795711Apr 2, 2007Aug 5, 2014Mati Therapeutics Inc.Drug delivery methods, structures, and compositions for nasolacrimal system
US8801649Oct 5, 2010Aug 12, 2014Transcend Medical, Inc.Glaucoma treatment device
US8808220Oct 14, 2010Aug 19, 2014Transcend Medical, Inc.Ocular pressure regulation
US8814819Dec 16, 2010Aug 26, 2014Transcend Medical, Inc.Glaucoma treatment device
US8945038May 17, 2013Feb 3, 2015Transcend Medical, Inc.Internal shunt and method for treating glaucoma
US9011361Sep 5, 2008Apr 21, 2015Mati Therapeutics Inc.Lacrimal implant detection
US9084662Jan 17, 2007Jul 21, 2015Transcend Medical, Inc.Drug delivery treatment device
US9089392Aug 23, 2013Jul 28, 2015Transcend Medical, Inc.Drug delivery devices and methods
US9132088Apr 29, 2009Sep 15, 2015Mati Therapeutics Inc.Composite lacrimal insert and related methods
US9155656Feb 10, 2014Oct 13, 2015Transcend Medical, Inc.Delivery system for ocular implant
US9168222Apr 29, 2014Oct 27, 2015Mati Therapeutics Inc.Nasolacrimal drainage system implants for drug therapy
US9173773Jun 7, 2007Nov 3, 2015Johnson & Johnson Vision Care, Inc.Punctal plugs for the delivery of active agents
US9180045Apr 7, 2011Nov 10, 2015Mati Therapeutics Inc.Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US9216108Feb 17, 2009Dec 22, 2015Mati Therapeutics Inc.Lacrimal implants and related methods
US9241832Apr 18, 2013Jan 26, 2016Transcend Medical, Inc.Delivery system for ocular implant
US9259351Nov 21, 2012Feb 16, 2016Johnson & Johnson Vision Care, Inc.Punctal plugs
US9259352Nov 21, 2012Feb 16, 2016Johnson & Johnson Vision Care, Inc.Punctal plugs
US9351873Mar 6, 2014May 31, 2016Transcend Medical, Inc.Ocular pressure regulation
US9398977Aug 22, 2014Jul 26, 2016Transcend Medical, Inc.Glaucoma treatment device
US9421127Nov 21, 2012Aug 23, 2016Johnson & Johnson Vision Care, Inc.Punctal plugs
US9421130Aug 4, 2015Aug 23, 2016Novartis Ag.Glaucoma treatment device
US20070243230 *Apr 2, 2007Oct 18, 2007Forsight Labs, LlcNasolacrimal Drainage System Implants for Drug Therapy
US20070298075 *Jun 7, 2007Dec 27, 2007Borgia Maureen JPunctal plugs for the delivery of active agents
US20070299516 *Jun 7, 2007Dec 27, 2007Han CuiPunctal plugs for the delivery of active agents
US20080045911 *Jun 7, 2007Feb 21, 2008Borgia Maureen JPunctal plugs for the delivery of active agents
US20080057106 *Aug 29, 2007Mar 6, 2008Erickson Signe RLow profile bioactive agent delivery device
US20080107713 *Nov 8, 2006May 8, 2008Orilla Werhner CContact lens as a sustained drug delivery implant
US20080317819 *Jun 21, 2007Dec 25, 2008Orilla Werhner CIop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090092654 *Dec 10, 2008Apr 9, 2009Qlt Plug Delivery, Inc.Drug Delivery Methods, Structures, and Compositions for Nasolacrimal System
US20090098584 *Aug 30, 2006Apr 16, 2009Bristol-Myers Squibb CompanyBiomarkers and Methods for Determining Sensitivity to Vascular Endothelial growth factor Receptor-2 Modulators
US20090099626 *Sep 5, 2008Apr 16, 2009Qlt Plug Delivery, Inc. - QpdiLacrimal implant detection
US20090104248 *Sep 8, 2008Apr 23, 2009Qlt Plug Delivery, Inc. -QpdiLacrimal implants and related methods
US20090118702 *Jul 1, 2005May 7, 2009Forsight Labs, LlcTreatment Medium Delivery Device and Methods for Delivery of Such Treatment Mediums to the Eye Using such a Delivery Device
US20090264861 *Feb 17, 2009Oct 22, 2009Qlt Plug Delivery, Inc.Lacrimal implants and related methods
US20090318549 *Jun 24, 2009Dec 24, 2009Qlt Plug Delivery, Inc.Combination treatment of glaucoma
US20100114309 *Dec 21, 2007May 6, 2010De Juan Jr EugeneDrug delivery implants for inhibition of optical defects
US20100158980 *Dec 18, 2008Jun 24, 2010Casey KopczynskiDrug delivery devices for delivery of therapeutic agents
US20100209477 *Jan 22, 2010Aug 19, 2010Qlt Plug Delivery Inc.Sustained release delivery of one or more agents
US20100256578 *Mar 29, 2010Oct 7, 2010Victor LustPunctal Plugs
US20100274204 *Feb 23, 2010Oct 28, 2010Qlt Plug Delivery, Inc.Lacrimal implants and related methods
US20100274224 *Oct 28, 2010Qlt Plug Delivery, Inc.Lacrimal implant body including comforting agent
US20140161863 *Feb 14, 2014Jun 12, 2014Mati Therapeutics, Inc.Drug delivery methods, structures, and compositions for nasolacrimal system
EP2032101A2 *Jun 15, 2007Mar 11, 2009Johnson & Johnson Vision Care Inc.Punctal plugs for the delivery of active agents
EP2032101B1 *Jun 15, 2007Apr 29, 2015Johnson & Johnson Vision Care, Inc.Punctal plugs for the delivery of active agents
EP2844224A4 *Feb 27, 2013Feb 24, 2016Mati Therapeutics IncDrug delivery system and methods of treating open angle glaucoma and ocular hypertension
WO2007149771A2 *Jun 15, 2007Dec 27, 2007Johnson & Johnson Vision Care, Inc.Punctal plugs for the delivery of active agents
WO2007149771A3 *Jun 15, 2007Feb 21, 2008Johnson & Johnson Vision CarePunctal plugs for the delivery of active agents
WO2008083118A1 *Dec 21, 2007Jul 10, 2008Qlt Plug Delivery, Inc.Drug delivery implants for inhibition of optical defects
WO2008094989A2Jan 30, 2008Aug 7, 2008Alcon Research, Ltd.Punctal plugs and methods of delivering therapeutic agents
WO2011066479A1Nov 26, 2010Jun 3, 2011Qlt Plug Delivery, Inc.Lacrimal implants including split and insertable drug core
Classifications
U.S. Classification424/427, 514/253.08, 514/312, 514/223.2, 514/573, 514/355
International ClassificationA61K31/549, A61K31/4709, A61K31/496, A61K31/557
Cooperative ClassificationA61F9/00772, A61F9/0017, A61K9/0051
European ClassificationA61K9/00M16B, A61F9/00B2, A61F9/007T
Legal Events
DateCodeEventDescription
Dec 20, 2006ASAssignment
Owner name: FORSIGHT LABS, LLC, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ODRICH, STEVEN A.;REEL/FRAME:018661/0445
Effective date: 20061124
Feb 5, 2008ASAssignment
Owner name: QLT PLUG DELIVERY, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORSIGHT LABS, LLC;REEL/FRAME:020467/0510
Effective date: 20080201
Feb 11, 2008ASAssignment
Owner name: QLT PLUG DELIVERY, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GLAZER, LIANE C;REEL/FRAME:020490/0280
Effective date: 20080207
Feb 13, 2008ASAssignment
Owner name: FORSIGHT NEWCO II, INC., DELAWARE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORSIGHT LABS, LLC;REEL/FRAME:020505/0745
Effective date: 20071018
Feb 25, 2008ASAssignment
Owner name: QLT PLUG DELIVERY, INC., DELAWARE
Free format text: CHANGE OF NAME;ASSIGNOR:FORSIGHT NEWCO II, INC.;REEL/FRAME:020553/0219
Effective date: 20071018
Apr 26, 2011ASAssignment
Owner name: 3088922, INC., DELAWARE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:QLT PLUG DELIVERY, INC.;REEL/FRAME:026182/0792
Effective date: 20101215
Owner name: QLT INC., CANADA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:3088922, INC.;REEL/FRAME:026182/0770
Effective date: 20110215
Apr 23, 2013ASAssignment
Owner name: MATI THERAPEUTICS INC., TEXAS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:QLT INC.;REEL/FRAME:030266/0677
Effective date: 20130413